MUNICH, Germany, Jan. 20, 2021 — XClinical, a leading vendor of eClinical
software has announced a merger with France-based Carenity, a social platform supporting
patients and caregivers worldwide, and Fortress Medical Systems, the US-based vendor
of Clindex®, an integrated CTMS and EDC system. All three companiesare long-established,
leading providers in their respective markets. The group is financed by German
Private Equity firm BID Equity. Together, the three businesses will form a new,
innovative data science company, powered by cutting edge technology. The group brings
best in class data science and eClinical software solutions together, delivering
end-to-end coverage of the clinical development process for their 150+
customers in over 20 countries, including US, Germany, France, UK, Italy, Japan
and China.
Biopharma, Medical Device as well as Academic
sponsors and CROs worldwide will benefit from progressive and cost-efficient
solutions such as feasibility studies, Real World Evidence data collection,
patient recruitment, market access support in combination with EDC, CTMS, IWRS,
eTMF, RBM and eCOA.
About XClinical
XClinical, a leading international provider of
eClinical software solutions, has been the first acquisition in BID Equity’s
Life Sciences portfolio. The company was founded 2002 in Munich, Germany with a
vision to build a new EDC system leveraging CDISC standards to accelerate the
database build and reduce data management programming efforts. XClinical’s Marvin
is one of the world’s most established eClinical solutions, helping clinical
study sponsors and CROs harness the power of their data to better manage
clinical trials.
Carenity is a leading social platform
supporting 500,000 patients and caregivers worldwide, across 1,000 chronic and
rare diseases.
Through its award-winning platform and data
science expertise, Carenity provides direct, timely and compliant access to
patient real-world data. Founded in 2011 and headquartered in Paris, Carenity
offers unique solutions for Real-World Evidence, Clinical Trial Optimization as
well as Scientific Communication.
About Fortress Medical Systems
Fortress Medical Systems was founded in 1997
with the launch of Clindex®, one of the first integrated software systems
designed for clinical trials. Over the years, Clindex® has been used to support
medical device pharmaceutical, diagnostic and combination product studies. By working closely with their customers, the
Fortress Medical team managed to grow the functionality of Clindex® so it is
one of the most flexible and comprehensive systems on the market today. The client base spans the world. As a testament to the scalability of
Clindex®, clients range from Fortune 500 corporations to small, start-up
companies and include many contract Clinical Research Organizations as well.
Fortress Medical Systems, Accelerate Diagnostics won the Clinical Trial Process Innovation at the 2019 Clinical and Research Excellence (CARE) Awards. The award win was announced during a ceremony presented by Ben Nemzer at the Hyatt Regency Boston, US on May 2, 2019.
Now in its fourth year, the CARE Awards drew a crowd of pharmaceutical and biomedtech industry leaders and innovators from companies both large and small, who gathered to celebrate the achievements of those working to advance the quality of healthcare worldwide by bringing new and needed medicines to market. Categories for the awards spanned the full spectrum of the drug development process, and the winners of these prestigious trophies were as diverse as the categories themselves.
Streamlining the approach and methods for uploading trial device data is a notable innovation in the current clinical research climate where devices are increasingly deployed in trials. The remarkable 50% reduction in data entry time and resultant savings in mandays achieved with the CLINDEX XML solution were impressive.
About Informa Pharma Intelligence Trusted by over 3,000 of the world’s leading pharmaceutical companies, CROs, med and biotech organizations, and healthcare service providers, the Pharma Intelligence suite of intelligence solutions delivers vital, accurate, and timely intelligence about the drug development pipeline to pharmaceutical and biomedical decision makers around the world.
At Pharma Intelligence, global teams of subject area experts follow and analyze key diseases, clinical trials, drug approvals and R&D activities as part of the breadth and depth of data available to customers. For more information visit pharmaintelligence.informa.com.
